Press coverage about Hospira (NYSE:HSP) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hospira earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the healthcare company an impact score of 44.7519482976364 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

TRADEMARK VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-hospira-nysehsp-stock-price/1470972.html.

About Hospira

Hospira, Inc provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company’s portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products.

Insider Buying and Selling by Quarter for Hospira (NYSE:HSP)

Receive News & Ratings for Hospira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hospira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.